High dose versus low dose standardized cranberry proanthocyanidin extract for the prevention of recurrent urinary tract infection in healthy women: a double-blind randomized controlled trial
Autor: | Denis Guyonnet, Valérie Bochard, Sylvie Dodin, Stéphanie Dudonné, Asma Babar, Vicky Leblanc, Lynne Moore, Yves Desjardins, Simone Lemieux |
---|---|
Rok vydání: | 2021 |
Předmět: |
Adult
0301 basic medicine medicine.medical_specialty Adolescent Urology Urinary system Urine Bacteriuria lcsh:RC870-923 Rate ratio law.invention Young Adult 03 medical and health sciences 0302 clinical medicine Double-Blind Method Randomized controlled trial Recurrence law Internal medicine Humans Medicine Women Proanthocyanidins Cranberry 030212 general & internal medicine Plant Extracts business.industry Prevention General Medicine Middle Aged Urinary tract infections lcsh:Diseases of the genitourinary system. Urology medicine.disease Pyuria Clinical trial Vaccinium macrocarpon 030104 developmental biology Reproductive Medicine Proanthocyanidin Female medicine.symptom business Phytotherapy Research Article |
Zdroj: | BMC Urology, Vol 21, Iss 1, Pp 1-13 (2021) BMC Urology |
ISSN: | 1471-2490 |
DOI: | 10.1186/s12894-021-00811-w |
Popis: | Purpose Our objective was to assess the efficacy of a high dose cranberry proanthocyanidin extract for the prevention of recurrent urinary tract infection. Material and methods We recruited 145 healthy, adult women with a history of recurrent urinary tract infection, defined as ≥ 2 in the past 6 months or ≥ 3 in the past 12 months in this randomized, controlled, double-blind clinical trial. Participants were randomized to receive a high dose of standardized, commercially available cranberry proanthocyanidins (2 × 18.5 mg daily, n = 72) or a control low dose (2 × 1 mg daily, n = 73) for a 24-week period. During follow-up, symptomatic women provided urine samples for detection of pyuria and/or bacteriuria and received an appropriate antibiotic prescription. The primary outcome for the trial was the mean number of new symptomatic urinary tract infections during a 24-week intervention period. Secondary outcomes included symptomatic urinary tract infection with pyuria or bacteriuria. Results In response to the intervention, a non-significant 24% decrease in the number of symptomatic urinary tract infections was observed between groups (Incidence rate ratio 0.76, 95%CI 0.51–1.11). Post-hoc analyses indicated that among 97 women who experienced less than 5 infections in the year preceding enrolment, the high dose was associated with a significant decrease in the number of symptomatic urinary tract infections reported compared to the low dose (age-adjusted incidence rate ratio 0.57, 95%CI 0.33–0.99). No major side effects were reported. Conclusion High dose twice daily proanthocyanidin extract was not associated with a reduction in the number of symptomatic urinary tract infections when compared to a low dose proanthocyanidin extract. Our post-hoc results reveal that this high dose of proanthocyanidins may have a preventive impact on symptomatic urinary tract infection recurrence in women who experienced less than 5 infections per year. Trial registration: Clinicaltrials.gov, identifier NCT02572895 |
Databáze: | OpenAIRE |
Externí odkaz: |